An anti-angiogenic compound

An angiogenesis, compound technology, applied in cardiovascular system diseases, organic chemistry, drug combination, etc., can solve the problem of high price

Active Publication Date: 2016-08-17
NINGBO FANGCHANG PHARMA CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, because Lucentis is an antibody drug and its price is extremely high, it cannot be popularized all over the world

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An anti-angiogenic compound
  • An anti-angiogenic compound
  • An anti-angiogenic compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] The preparation of embodiment 1 intermediate of the present invention

[0068]

[0069] Proceed as follows:

[0070] Step 1: Mix Michaelis acid (75.3 g, 0.522 mol) and triethyl orthoformate (92 mL, 0.55 mol), heat to 55°C for 90 minutes, then cool to 45°C. Compound 1 (92g, 0.5mol) was dissolved in methanol (200mL), and added to the reaction mixture to react for 45 minutes while keeping the temperature of the reaction mixture below 50°C, then stirred overnight at room temperature, thin layer chromatography (PE / EA =3:1) Monitor until the reaction is complete. The reaction mixture was cooled to 0°C, and the precipitate was filtered and dried to obtain pure compound 2 (155.9 g, yield: 96%) as a white solid.

[0071] Step 2: Compound 2 (155.9g, 0.441mol) was heated to 100°C in a Dowtherm A heat pipe (1.1L), and then slowly added to a flask connected to a Dowtherm A heat pipe (500mL, preheated to 210 °C), while maintaining the temperature above 207 °C. The reactants we...

Embodiment 2

[0079] Preparation of Example 2 Compound V01 (also denoted as V01 in the present invention)

[0080] step 1:

[0081]

[0082] Compound 11A (20 g, 0.15 mol), DMAP (1.9 g, 15.4 mmol) and (BoC) 2 O (75 g, 0.34 mol) was mixed in tetrahydrofuran (750 mL), and the reaction mixture was stirred at room temperature overnight. Thin layer chromatography (PE / EA=3:1) showed that the reaction was complete. The reaction mixture was concentrated, suspended in PE / EA (10:1, 200 mL), and filtered to obtain pure compound 11 (50 g, 100%) as a white solid.

[0083] Step 2:

[0084]

[0085] Mix compound 10 (50 mg, 0.15 mmol) and Cs2CO3 (150 mg, 0.45 mmol) in DMSO (1 mL), stir at room temperature under N2 for half an hour, then add compound 11 (60 mg). The resulting reaction mixture was stirred for half an hour and was detected by thin layer chromatography (DCM / methanol=10:1) until the reaction was complete. The reaction mixture was diluted with water, extracted with EA, the organic phas...

Embodiment 3

[0087] Preparation of Example 3 Compound V3 (also denoted as V03 in the present invention)

[0088] step 1:

[0089]

[0090] Stir and mix compound 13 (5.0g, 45mmol) and pyridine (200mL), and (Boc) 2 O (14.7 g, 67.5 mmol) was added dropwise to the above mixture. After the addition, the reaction was stirred at 85 °C for 4 hours. Thin-layer chromatography (DCM / methanol=10:1) tracked to the completion of the reaction, cooled the reaction mixture to 0 °C, added concentrated HCl (100 mL) and H2O (50 mL), after EA extraction, collected the organic phase and washed it with NaHCO3 aqueous solution , after drying over Na2SO4, a yellow oil was obtained, which was suspended in Et2O and filtered to obtain white solid compound 14 (4.3 g, yield: 45.2%).

[0091] Stir and mix compound 14 (2.4g, 11.4mmol) and N,N dimethylaniline (6.6mL) in DCM (84mL), add POCl dropwise at 0°C under N2 3 (3.2 mL, 34.2 mmol). After the addition, the reaction mixture was stirred at room temperature for 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided in the present invention are a new anti-angiogenic compound and a preparation method and use thereof. The compound of the present invention has a good anti-angiogenic effect, and this compound is initially considered to act by inhibiting VEGFR2 (i.e. KDR), thereby generating activity. Such compounds can be used for the treatment of diseases caused by abnormal protein kinase such as neovascularization, VEGFR2, PDGFR-&bgr;, and KIT, for example, wet macular degeneration, malignant tumours etc.

Description

technical field [0001] The present invention relates to a new compound and its application. Background technique [0002] Angiogenesis is the process of sprouting new blood vessels from existing blood vessels. This process is associated with migration and proliferation of vascular endothelial cells. Angiogenesis is related to many major human diseases, such as malignant tumors. At present, it has been found that ocular angiogenesis diseases, including age-related macular degeneration (AMD), diabetic retinopathy, neovascular glaucoma, etc., are all characterized by abnormal proliferation of ocular neovascularization (Jin Xiao, et al. , Research progress on the application and mechanism of anti-VEGF drugs in ophthalmic diseases, Zhongwai Medical, 2012). [0003] Among them, there are mainly two types of macular degeneration: dry and wet. Wet macular degeneration (AMD) is characterized by new blood vessels in the choroid entering under the retina and subsequent pathological ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D401/12C07D471/04C07D487/04C07D417/12C07D417/14C07D401/14A61K31/506A61K31/519A61P27/06A61P27/02A61P9/10A61P3/10
CPCC07D401/12C07D401/14C07D403/12C07D417/12C07D417/14C07D471/04C07D487/04A61K31/506A61K31/519A61P3/10A61P9/10A61P27/02A61P27/06
Inventor 侯睿罗红蓉
Owner NINGBO FANGCHANG PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products